http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220031069-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00ed0a5297e0d8268188852ac2a885c3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2020-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8482c942098de12af4ca3a36d0b6c363 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108543e0a65b41b2cb8f93cf607c5767 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82814ee46fa7eede7f2b6821dcbef48b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a7f25f6ce7f50dc24aa6f323ca82f11 |
| publicationDate | 2022-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20220031069-A |
| titleOfInvention | Methods for diagnosing the effectiveness of anti-tumor treatment |
| abstract | The present invention relates to a method of predicting whether a subject having a tumor will respond to a tumor therapy selected from (i) immunotherapy, (ii) chemotherapy, (iii) anti-hormonal therapy, and (iv) anti-tyrosine kinase therapy. wherein the method comprises: (A) determining the level(s) of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from the subject, wherein the at least one nucleic acid molecule (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 6, (b) a nucleic acid molecule consisting of the nucleotide sequence of any one of SEQ ID NOs: 7 to 12, (c) ( a nucleic acid molecule encoding a polypeptide that is at least 85% homologous to the amino acid sequence of a), preferably at least 90% homologous, most preferably at least 95% homologous, (d) at least 95% homologous to the nucleotide sequence of (b) a nucleic acid molecule consisting of a nucleotide sequence that is homologous, preferably at least 96% homologous, most preferably at least 98% homologous, (e) a nucleic acid molecule consisting of a nucleotide sequence degenerate to the nucleic acid molecule of (d) , (f) consists of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment being at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, most preferably preferably a nucleic acid molecule comprising at least 600 nucleotides, and (g) a nucleic acid molecule of any one of (a) to (f), wherein T is selected from a nucleic acid molecule in which U is replaced, wherein at least one The protein or peptide is selected from the protein or peptide encoded by the nucleic acid molecule of any one of (a) to (g); and (B) the level(s) of (A) at least one nucleic acid molecule and/or at least one in a sample obtained from one or more subjects responding to one or more therapies of (i) to (iii) or a corresponding predetermined standard compared to the level(s) of a protein or peptide of , substantially the same or reduced level(s) of (A) as compared to the level(s) of (B) indicates that the subject will respond to the tumor therapy; or (B′) at least one nucleic acid molecule in a sample obtained from one or more subjects who have not responded to one or more therapies of (i) to (iii) or a corresponding predetermined standard, and/or (B′) level(s) of (A). compared to the level(s) of at least one protein or peptide, wherein the level(s) of (B′) or the reduced level(s) of (A) compared to a predetermined standard indicate that the subject will respond to the tumor therapy. and substantially the same or increased level(s) of (A) compared to the level(s) of (B′) indicates that the subject will not respond to tumor therapy. |
| priorityDate | 2019-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1234.